Evidence map›Paper›PMID 30055950›Full record

ReviewSeminars in cancer biology2019

Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers.

Qing Kay Li, Christian P Pavlovich, Hui Zhang, Christopher R Kinsinger, Daniel W Chan

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in cancer biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Mitochondria-ER crosstalk via MAMS: Bridging cellular homeostasis and cancer progression.Apoptosis : an international journal on programmed cell death · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Preoperative prediction of WHO/ISUP grade of ccRCC using intratumoral and peritumoral habitat imaging: multicenter study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Qing Kay LiDepartment of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, United States. Electronic address: qli23@jhmi.edu.
Christian P PavlovichDepartment of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, United States.
Hui ZhangDepartment of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, United States.
Christopher R KinsingerClinical Proteomic Tumor Analysis Consortium, NCI/NIH, Bethesda, MD, 20892, United States.
Daniel W ChanDepartment of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, United States.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

The Comprehensive Proteome Characterization Center at Johns Hopkins: High Precision Discovery and Confirmation of Genoproteomic TargetsU24CA210985 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2016 to 2020
$5.3M
NCI NIH HHS U24 CA210985
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, comprising approximately 75% of all kidney tumors. Recent the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) studies have significantly advanced the molecular characterization of RCC and facilitated the development of targeted therapies. Such advances have improved the median survival of patients with advanced disease from less than 10 months prior to 2004 to 30 months by 2011. However, approximately 30% of localized ccRCC patients will nevertheless develop recurrence or metastasis after surgical resection of their tumor. Therefore, it is critical to further analyze potential tumor-associated proteins and their profiles during disease progression. Over the past decade, tremendous effort has been focused on the study of molecular pathways, including genomics, transcriptomics, and proteomics in order to identify potential molecular biomarkers, as well as to facilitate early detection, monitor tumor progression and uncover potentially therapeutic targets. In this review, we focus on recent advances in the proteomic analysis of ccRCC, current strategies and challenges, and perspectives in the field. This insight will highlight the discovery of tumor-associated proteins, and their potential clinical impact on personalized precision-based care in ccRCC.

Indexed as

ProteomicsBiomarkers, TumorCarcinoma, Renal CellGene Expression Regulation, NeoplasticGenomicsHumansProteomeBiomarkers, TumorProteomeClear cell renal cell carcinoma (ccRCC)Clinical applicationPersonalized medicineProtein profilingProteomics

Identifiers

PMID30055950
PMCPMC6624650
OpenAlexW2883869155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.